Barclays Maintains an 'Equalweight' on Synta Pharma. (SNTA); Early Ganetespib Activity Encouraging
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Synta Pharma. (NASDAQ: SNTA), PT $4.
Barclays analyst says, "We are maintaining our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
